Leveraging their expertise in lipid science and the potential benefits of polyunsaturated fatty acids, Amarin Corporation plc focuses on the commercialization and development of cardiovascular therapeutics. Their first FDA approved product, Vascepa®, is available in the United States by prescription. With a goal to address cardiovascular risk for millions of patients globally, Amarin Corporation plc is positioned to create a new paradigm in cardiovascular disease management. For more information, visit their website at www.amarincorp.com.